Potential biological factor contributing to racial disparities in prostate cancer

December 8, 2013, American Association for Cancer Research

Researchers have uncovered a potential biological factor that may contribute to disparities in prostate cancer incidence and mortality between African-American and non-Hispanic white men in the United States, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9.

In the United States, African-American men are 1.5 times more likely to develop and more than twice as likely to die from the disease compared with non-Hispanic white men.

"The causes of prostate cancer disparities are numerous, complex, often interrelated, and only partially understood," said David P. Turner, Ph.D., assistant professor in the Department of Pathology and Laboratory Medicine at the Medical University of South Carolina in Charleston. "We have identified a potential relationship between sugar-derived metabolites and cancer that may provide a biological link with socioeconomic and environmental factors known to contribute to prostate cancer disparities.

"As our bodies use the sugars that we consume for energy they generate waste products, or metabolites, including molecules called advanced glycation end products, or AGEs," Turner explained. "AGEs naturally accumulate in our tissue as we grow older, and they have been implicated in diseases associated with aging such as diabetes, heart disease, and Alzheimer's disease. They can also cause increased inflammation and the generation of potentially harmful chemicals known as reaction oxygen species, which both promote cancer.

"Critically, a common source of the AGEs that accumulate in our bodies is the foods we eat, which has significant implications for cancer health disparities and our overall health.

"We found that AGE levels were highest in African-American men with prostate cancer," said Turner. "Because obesity, poor eating habits, and an inactive lifestyle all promote AGE accumulation, and these factors are often more evident in African-Americans, we hypothesize that there is a link between these factors that could help explain why African-American men are more likely to develop prostate cancer and die from the disease."

Turner and colleagues examined circulating and intratumoral AGE levels in 16 African-American and 16 non-Hispanic white men with prostate cancer. They found that AGE levels were higher in serum from cancer patients compared with individuals without cancer. When analyzing AGE levels in prostate tumor samples, levels were highest in tumor samples from African-American patients. In addition, AGE levels in correlated with levels of a molecule to which AGEs bind to mediate their effects, called receptor for AGE (RAGE).

"We think that the AGE-RAGE signaling pathway promotes prostate cancer and that increased AGE accumulation may represent a biological mechanism promoting prostate cancer disparity," said Turner.

Explore further: African Americans experience longer delays between diagnosis and treatment of prostate cancer

More information: Abstract Number: PR10

Presenter: David P. Turner, Ph.D.

Title: Advanced glycation end-products are increased in prostate cancer and may promote racial disparity

Authors: David P. Turner, Victoria J. Findlay, Lourdes M. Nogueira, Sadia Robinson, Emily Kistner-Griffin, Laura Spruill, Ryan Y. Turner, Mahtabuddin Ahmed, Judith D. Salley, Marvella E. Ford.

African American cancer patients are more likely to die of their disease than their European counterparts. Our research has identified a potential mechanistic link between carbohydrate derived metabolites and cancer associated pathways which may provide a biological consequence of the socioeconomic and environmental factors that are known to drive cancer health disparity.
Glycation is the non-enzymatic glycosylation of sugar moieties to biological macromolecules such as protein and DNA which produces reactive metabolites known as advanced glycation end products (AGE's). AGE's accumulate in our tissues as we grow older and drive many of the complications associated with diseases displaying health disparity including diabetes, metabolic syndrome, Alzheimer's and heart disease. Low income, obesity and an inactive/sedentary lifestyle are established factors driving cancer health disparity. Apart from their production during normal metabolism, AGE's are also formed through the ingestion of food and by external environmental factors such as lack of exercise. AGE content in the Western Diet has consistently increased over the last 50 years due to increased consumption of sugar laden and cheap processed/manufactured foods which are high in reactive AGE metabolites and can promote obesity.
We therefore examined circulating and intra-tumoral AGE metabolite levels in clinical specimens and identified a race specific, tumor dependent pattern of accumulation in prostate cancer serum and tumor. In mouse xenograft models, AGE accumulation was highest in the more aggressive tumors. One way AGE's mediate their deleterious effects is by functioning as ligand for the trans-membrane receptor for AGE (RAGE). In diabetes and other diseases, the AGE-RAGE signaling axis is a pro-inflammatory pathway leading to the upregulation of pro-inflammtory cytokines through increased NFkB activation. Higher AGE levels in prostate tumors corresponded with higher RAGE expression and increased NFkB transcriptional activity. In immortalized prostate cancer cell lines AGE treatment increased cancer associated processes and RAGE expression levels. Loss of function studies show that AGE mediated increases in cancer associated processes was dependent upon RAGE expression.
These data implicate the AGE-RAGE signaling axis as a potential biological mechanism promoting prostate cancer and indicate that increased AGE accumulation may represent a biological mechanism promoting prostate cancer disparity.

Related Stories

African Americans experience longer delays between diagnosis and treatment of prostate cancer

May 28, 2013
Among men with prostate cancer, African Americans experience longer treatment delays after being diagnosed than Caucasians. That is the finding of an analysis published early online in CANCER, a peer-reviewed journal of the ...

Early-onset baldness in African-American men may be linked to prostate cancer

March 26, 2013
Baldness was associated with an increased risk of prostate cancer among African-American men, and risk for advanced prostate cancer increased with younger age and type of baldness, according to data published in Cancer Epidemiology, ...

Genetic differences may cause higher rates of prostate cancer in African-American men

September 20, 2011
Genetic differences in prostate cells seem to be a root cause of the prostate cancer disparities between African-American men and white men, according to findings presented at the Fourth AACR Conference on The Science of ...

Exercise linked with reduced prostate cancer risk in Caucasians but not African Americans

February 11, 2013
A new study suggests that exercise may reduce Caucasian men's risk of developing prostate cancer. And among Caucasian men who do have prostate cancer, exercise may reduce their risk of having more serious forms of the disease. ...

African Americans experience longer delay between prostate cancer diagnosis and treatment

April 1, 2013
African American men on average wait a week longer than their Caucasian counterparts between the initial diagnosis of prostate cancer and treatment, according to University of North Carolina researchers.

Weight at time of diagnosis linked to prostate cancer mortality

October 29, 2013
Men who are overweight or obese when they are diagnosed with prostate cancer are more likely to die from the disease than men who are of healthy weight, according to a Kaiser Permanente study published today in the journal ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.